More on INKT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+17.9% Growth)
- Ratings (7.5 Score)

Upcoming Events

- Earnings (8/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

MiNK Therapeutics (NQ:INKT)
Delayed: 12.14 -0.07 (0.57%)
Prev. Close $12.21  
Open$12.07 
52 Wk High$ 
52 Wk Low$ 
Day High$12.45 
Day Low$11.86 
P/E N/A  
EPS$ 
Volume16,574 

Friends, Peers and Foes (?): AGEN (more...)

Jun 5, 2026 06:04 PM Form 4 MiNK Therapeutics, Inc. For: Jun 04 Filed by: Ryan Barbara
Jun 3, 2026 04:30 PM MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
Jun 2, 2026 04:06 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Holcomb John Bradley
Jun 2, 2026 04:06 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Ryan Barbara
Jun 2, 2026 04:06 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Corvese Brian
Jun 2, 2026 04:05 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Behner Peter
Jun 2, 2026 04:05 PM Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: WIINBERG ULF
May 28, 2026 09:05 AM MiNK Therapeutics doses first patient in phase 2 lung injury trial
May 28, 2026 09:04 AM MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
May 21, 2026 05:00 PM Agenus reports AI analysis shows improved response rates for cancer treatment
View All Articles

Entities mentioned with INKT

View All Entities